Fundamental Analysis

Ratin / 24 Sep 2026 / Categories: Flash News Investment App, Recommendations

1 stock recommendation each based on Fundamental and Technical analysis along with timely review to provide you with handsome profits.

1 stock recommendation each based on Fundamental and Technical analysis along with timely review to provide you with handsome profits.[EasyDNNnews:PaidContentStart]

WOCKHARDT LTD
Ticker: 532300
BUY: ₹2,290.10
Target: ₹2,550.00

Wockhardt is a global pharmaceutical and biotechnology organisation engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals, and topicals. The company offers different products for various regions, with EMROK, METHYCOBAL 500 MCG 15T, and METHYCOBAL INJ 1 ML being a few examples in the Indian market. In Q1FY27, the company reported strong business growth, with revenue from operations rising 35 per cent YoY to Rs 594 crore compared with Rs 438 crore in Q1FY26. Foreign Institutional Investor (FII) holdings in the company have been steadily increasing over the past three quarters, reaching a current holding of 7.23 per cent. The company has also hit a milestone by achieving FDA approval from the USA for ZAYNICH™, the very first Indian-originated and discovered New Chemical Entity (NCE). With a powerful geographic revenue composition spread across the UK, Emerging Markets, India, and Ireland, and with strong financial performance, we recommend BUY.

[EasyDNNnews:PaidContentEnd] [EasyDNNnews:UnPaidContentStart]

To read the entire article, you must be a FNI Weekly Subscriber.

[EasyDNNnews:UnPaidContentEnd]